NASDAQ:NEO NeoGenomics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $35.79 +0.93 (+2.67 %) (As of 09/18/2020 09:44 AM ET) Add Compare Share Today's Range$35.50Now: $35.79▼$36.1750-Day Range$34.92MA: $38.20▼$40.4852-Week Range$18.52Now: $35.79▼$41.03Volume3,695 shsAverage Volume936,130 shsMarket Capitalization$3.95 billionP/E RatioN/ADividend YieldN/ABeta0.8 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingNeoGenomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.18, NeoGenomics has a forecasted upside of 6.7% from its current price of $34.86.Amount of Analyst CoverageNeoGenomics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesNeoGenomics has received 420 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeoGenomics has received 289 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeoGenomics has received 59.24% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote “Outperform” if you believe NEO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeoGenomics does not currently pay a dividend.Dividend GrowthNeoGenomics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeoGenomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,498,701.00 in company stock.Percentage Held by InsidersOnly 6.50% of the stock of NeoGenomics is held by insiders.Percentage Held by Institutions91.67% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeoGenomics are expected to grow in the coming year, from ($0.01) to $0.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeoGenomics is -697.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeoGenomics is -697.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoGenomics has a P/B Ratio of 7.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.43 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Testing laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NEO Previous Symbol CUSIPN/A CIK1077183 Webwww.neogenomics.com Phone239-768-0600Debt Debt-to-Equity Ratio0.25 Current Ratio6.79 Quick Ratio6.44Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$408.83 million Price / Sales9.67 Cash Flow$0.52 per share Price / Cash Flow68.27 Book Value$4.86 per share Price / Book7.36Profitability EPS (Most Recent Fiscal Year)$0.23 Net Income$8.01 million Net Margins-1.33% Return on Equity0.73% Return on Assets0.51%Miscellaneous Employees1,700 Outstanding Shares110,431,000Market Cap$3.95 billion Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $35.79 +0.93 (+2.67 %) (As of 09/18/2020 09:44 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NEO News and Ratings via Email Sign-up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter. NeoGenomics (NASDAQ:NEO) Frequently Asked Questions How has NeoGenomics' stock been impacted by COVID-19? NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NEO shares have increased by 40.7% and is now trading at $34.86. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of NeoGenomics? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NeoGenomics. When is NeoGenomics' next earnings date? NeoGenomics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for NeoGenomics. How were NeoGenomics' earnings last quarter? NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Tuesday, July, 28th. The medical research company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.10) by $0.06. The medical research company earned $86.90 million during the quarter, compared to analysts' expectations of $86.55 million. NeoGenomics had a negative net margin of 1.33% and a positive return on equity of 0.73%. NeoGenomics's revenue for the quarter was down 14.6% on a year-over-year basis. During the same period last year, the business earned $0.07 EPS. View NeoGenomics' earnings history. What price target have analysts set for NEO? 12 brokers have issued twelve-month target prices for NeoGenomics' shares. Their forecasts range from $9.00 to $46.00. On average, they expect NeoGenomics' share price to reach $37.18 in the next twelve months. This suggests a possible upside of 6.7% from the stock's current price. View analysts' price targets for NeoGenomics. Who are some of NeoGenomics' key competitors? Some companies that are related to NeoGenomics include Alnylam Pharmaceuticals (ALNY), Bio-Rad Laboratories (BIO), Quest Diagnostics (DGX), BioNTech (BNTX), Insulet (PODD), Steris (STE), Bio-Rad Laboratories (BIO.B), BioMarin Pharmaceutical (BMRN), Eurofins Scientific (ERFSF), Cardinal Health (CAH), Catalent (CTLT), Smith & Nephew (SN), Avantor (AVTR), Livongo Health (LVGO) and ABIOMED (ABMD). View all competitors. What other stocks do shareholders of NeoGenomics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology Group (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Inseego (INSG), Micron Technology (MU), Square (SQ), Paypal (PYPL), AbbVie (ABBV), Intel (INTC) and InVitae (NVTA). Who are NeoGenomics' key executives? NeoGenomics' management team includes the following people: Mr. Douglas M. VanOort, Chairman & CEO (Age 64)Ms. Sharon A. Virag, Chief Financial Officer (Age 52)Dr. Lawrence M. Weiss M.D., Chief Scientific Officer (Age 62)Mr. William Bishop Bonello, Chief Strategy & Corp. Devel. Officer and Director of Investor Relations (Age 54)Mr. George A. Cardoza, Pres of Pharma Services Division (Age 57) What is NeoGenomics' stock symbol? NeoGenomics trades on the NASDAQ under the ticker symbol "NEO." Who are NeoGenomics' major shareholders? NeoGenomics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.18%), Kopp Family Office LLC (4.22%), Emerald Advisers LLC (1.35%), Bank of New York Mellon Corp (1.29%), Emerald Mutual Fund Advisers Trust (1.24%) and Federated Hermes Inc. (0.93%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View institutional ownership trends for NeoGenomics. Which major investors are selling NeoGenomics stock? NEO stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Glenmede Trust Co. NA, Driehaus Capital Management LLC, Goldman Sachs Group Inc., Federated Hermes Inc., Falcon Point Capital LLC, Prudential Financial Inc., and Bank of New York Mellon Corp. Company insiders that have sold NeoGenomics company stock in the last year include George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Oort Douglas M Van, Robert J Shovlin, Steven C Jones, and William Bonello. View insider buying and selling activity for NeoGenomics. Which major investors are buying NeoGenomics stock? NEO stock was purchased by a variety of institutional investors in the last quarter, including Bellevue Group AG, Vanguard Group Inc., RTW Investments LP, Jennison Associates LLC, Nordea Investment Management AB, American Capital Management Inc., Scout Investments Inc., and New York State Common Retirement Fund. View insider buying and selling activity for NeoGenomics. How do I buy shares of NeoGenomics? Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is NeoGenomics' stock price today? One share of NEO stock can currently be purchased for approximately $34.86. How big of a company is NeoGenomics? NeoGenomics has a market capitalization of $3.85 billion and generates $408.83 million in revenue each year. The medical research company earns $8.01 million in net income (profit) each year or $0.23 on an earnings per share basis. NeoGenomics employs 1,700 workers across the globe. What is NeoGenomics' official website? The official website for NeoGenomics is www.neogenomics.com. How can I contact NeoGenomics? NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected] This page was last updated on 9/18/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
